Dauricine was predicted to have interactions with six AD-related targets: MAO-A, AChE, dopamine receptor D1 (D1 receptor), 5-HT1A, MAO-B and beta-secretase 1 (BACE1). This evidence concerns the gene BACE1 and Alzheimer disease.